---
figid: PMC4333206__nihms641464f1
figtitle: Notch receptors (Notch1-4) and ligands (DLL1, 3 and 4, Jagged 1-2) are expressed
  in tumor, normal, and endothelial cells
organisms:
- NA
pmcid: PMC4333206
filename: nihms641464f1.jpg
figlink: /pmc/articles/PMC4333206/figure/F1/
number: F1
caption: Notch receptors (Notch1-4) and ligands (DLL1, 3 and 4, Jagged 1-2) are expressed
  in tumor, normal, and endothelial cells. After ligand binding, the ICN is generated
  after cleavage events by ADAM/TACE proteases and γ-secretase. The ICN travels into
  the nucleus, interacts with multiple transcriptional regulators including CSL, displaces
  CoR, and recruits MAML to activate transcription of target genes. Potential cancer
  therapeutics that target Notch signaling include antibodies, peptides, miRNAs, TACE
  inhibitors, and GSIs. Notch can function as a tumor suppressor or is oncogenic and
  activate/inhibit different downstream targets depending on the malignancy and microenvironment.
papertitle: 'Molecular Pathways: Translational and Therapeutic Implications of the
  Notch Signaling Pathway in Cancer.'
reftext: Rebecca A. Previs, et al. Clin Cancer Res. ;21(5):955-961.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8890825
figid_alias: PMC4333206__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC4333206__F1
ndex: 172a59ed-df15-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4333206__nihms641464f1.html
  '@type': Dataset
  description: Notch receptors (Notch1-4) and ligands (DLL1, 3 and 4, Jagged 1-2)
    are expressed in tumor, normal, and endothelial cells. After ligand binding, the
    ICN is generated after cleavage events by ADAM/TACE proteases and γ-secretase.
    The ICN travels into the nucleus, interacts with multiple transcriptional regulators
    including CSL, displaces CoR, and recruits MAML to activate transcription of target
    genes. Potential cancer therapeutics that target Notch signaling include antibodies,
    peptides, miRNAs, TACE inhibitors, and GSIs. Notch can function as a tumor suppressor
    or is oncogenic and activate/inhibit different downstream targets depending on
    the malignancy and microenvironment.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - as
  - .na.character
  - an
  - Cdk2
  - dap
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - DCTN6-p27
  - CG9588
  - Smox
  - Mad
  - Diap2
  - Diap1
  - arm
  - bsk
  - p53
  - betaTub60D
  - hth
  - ra
  - Jag
  - Tace
  - Lst
  - Dll
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - AN
  - CDK2
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - SMAD1
  - SMAD4
  - SMAD5
  - SMAD6
  - SMAD7
  - SMAD9
  - SMAD2
  - SMAD3
  - ALPI
  - ALPP
  - CD47
  - IAPP
  - MAGT1
  - CTNNB1
  - MAPK8
  - MAPK9
  - MAPK10
  - NR4A1
  - TP53
  - TP63
  - TP73
  - DLL4
  - CES2
  - ADAM17
  - CCL1
---
